DSM

CAP Supports Discontinuing Term “Excited Delirium” as Cause of Death

Retrieved on: 
Friday, October 13, 2023

“Excited delirium” is not a medical diagnosis and should no longer be used as a cause of death.

Key Points: 
  • “Excited delirium” is not a medical diagnosis and should no longer be used as a cause of death.
  • The College of American Pathologists (CAP) supports this recent position issued by the National Association of Medical Examiners (NAME).
  • “Instead, NAME endorses—and CAP supports—that the death certificate list the underlying cause of death, natural or unnatural (to include trauma),” said Dr. Aurelius.
  • “If possible, the underlying cause should be determined and used for death certification.”

Fundamentals of The Texas ERCOT Electric Power Market: Register Now for the 2 Day Industry Seminar (Houston, United States - December 7-8, 2023) - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 12, 2023

The "Fundamentals of The Texas ERCOT Electric Power Market" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fundamentals of The Texas ERCOT Electric Power Market" training has been added to ResearchAndMarkets.com's offering.
  • Gain an understanding of the dynamic Texas wholesale and retail competitive markets, and learn how these markets interface with ERCOT ISO energy auctions and ISO operations.
  • Understand, enhance and apply knowledge of the ERCOT' nodal market operations for Energy, Ancillary Services, Market Settlements, Capacity, Retail and Renewables.
  • The key wholesale and retail stakeholders and market participants are, and how their activities shape ERCOT's operations.

Fortanix Introduces New Data Sovereignty Solutions To Help Organizations Meet Evolving Global Data Security and Privacy Requirements

Retrieved on: 
Tuesday, October 10, 2023

Fortanix® Inc. , the data security company and pioneer of Confidential Computing, today announced new capabilities for Fortanix Data Security Manager (DSM) to help public and private organizations address growing data sovereignty requirements globally.

Key Points: 
  • Fortanix® Inc. , the data security company and pioneer of Confidential Computing, today announced new capabilities for Fortanix Data Security Manager (DSM) to help public and private organizations address growing data sovereignty requirements globally.
  • Organizations around the globe are taking urgent steps to meet strict, complex, and changing data sovereignty regulations.
  • “Data sovereignty goes beyond just where data resides; it is a multi-layered approach that encompasses data security, protection, and privacy.
  • Fortanix will once again have a presence at it-sa Expo&Congress 2023, Europe's largest trade event for IT security.

dsm-firmenich provides additional pro forma financial information for 2022 and 2023

Retrieved on: 
Wednesday, October 4, 2023

The 2022 pro forma financials are prepared as a combination of the historical figures reported by DSM N.V. and Firmenich SA.

Key Points: 
  • The 2022 pro forma financials are prepared as a combination of the historical figures reported by DSM N.V. and Firmenich SA.
  • The 2022 pro forma financials are unaudited and include estimates, including for example approximations due to the different reporting currencies.
  • The reporting currency of dsm-firmenich is EUR.
  • - Intercompany profit elimination: HNC net sales were reduced by approximately €50m to eliminate ingredient sales to Firmenich.

Matica Bio Appoints Life Sciences Veterans Laura Parks, Heather N. Sugrue to Top Leadership Positions

Retrieved on: 
Thursday, September 14, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230914717415/en/
    Heather N. Sugrue, VP of Alliance Management at Matica Bio (Photo: Business Wire)
    Parks will drive Matica Bio’s commercial efforts, including sales team development, marketing, and strategy.
  • She brings to the company more than two decades of business leadership experience, driving the development of high-performance, market-focused teams in the life sciences.
  • Prior to Matica Bio, Parks served in senior roles for several life science companies and CDMOs, including Patheon Pharmaceuticals, where she led strategic commercial efforts, integrating diverse service offerings and driving global pricing initiatives.
  • “Their expertise will be an invaluable addition to Matica Bio as we serve our clients through our innovative manufacturing solutions in this rapidly growing industry.”

Source.ag Welcomes Trish Malarkey as Independent Director to the Board and Expands Leadership Team with a Suite of Senior Executives

Retrieved on: 
Tuesday, September 12, 2023

Rien Kamman, CEO and co-founder of Source.ag

Key Points: 
  • Rien Kamman, CEO and co-founder of Source.ag
    This follows a successful Series A funding round in the first half of 2023 which raised $27M.
  • The new appointments further boost Source.ag's ability to democratize access to fruit and vegetables without breaking planetary boundaries.
  • Trish Malarkey has been appointed as the independent Director to the board.
  • Malarkey highlighted: "I am thrilled to take on the role of Independent Director to the board at Source.ag at a very exciting time for the company.

Sirtex Medical Announces Collaboration Agreement with Magle Group for EmboCept® S DSM 50 μm

Retrieved on: 
Friday, September 8, 2023

WOBURN, Mass., Sept. 8, 2023 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the establishment of a collaboration and exclusive worldwide distribution agreement with Magle Group, a Sweden-based contract development and manufacturing organization as well as Degradable Starch Microspheres (DSM) sales and marketing company.

Key Points: 
  • Under the terms of the agreement, Sirtex will exclusively distribute Magle Group's chemoembolization product, EmboCept® S DSM 50 μm, in the existing and new geographic areas to support expanded patient access to the product.
  • Together, Sirtex and Magle also intend to establish a joint development plan to increase product range in the field of embolization by utilizing Magle Group's DSM platform.
  • Indicated for chemoembolization of liver and lung tumors, EmboCept® S DSM 50 μm is an adjuvant in the intra-arterial treatment of inoperable liver and lung tumors in combination with cytostatic agents.
  • EmboCept® S DSM 50 µm is currently approved for sale in Europe, Argentina, Singapore, and Malaysia.

Sirtex Medical Announces Collaboration Agreement with Magle Group for EmboCept® S DSM 50 μm

Retrieved on: 
Friday, September 8, 2023

WOBURN, Mass., Sept. 8, 2023 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the establishment of a collaboration and exclusive worldwide distribution agreement with Magle Group, a Sweden-based contract development and manufacturing organization as well as Degradable Starch Microspheres (DSM) sales and marketing company.

Key Points: 
  • Under the terms of the agreement, Sirtex will exclusively distribute Magle Group's chemoembolization product, EmboCept® S DSM 50 μm, in the existing and new geographic areas to support expanded patient access to the product.
  • Together, Sirtex and Magle also intend to establish a joint development plan to increase product range in the field of embolization by utilizing Magle Group's DSM platform.
  • Indicated for chemoembolization of liver and lung tumors, EmboCept® S DSM 50 μm is an adjuvant in the intra-arterial treatment of inoperable liver and lung tumors in combination with cytostatic agents.
  • EmboCept® S DSM 50 µm is currently approved for sale in Europe, Argentina, Singapore, and Malaysia.

EW Nutrition welcomes Jan Vanbrabant as new CEO

Retrieved on: 
Friday, September 1, 2023

VISBEK, Germany, Sept. 1, 2023 /PRNewswire/ -- EW Nutrition, a leading global provider of functional animal nutrition solutions, welcomes Jan Vanbrabant as its new Chief Executive Officer.

Key Points: 
  • VISBEK, Germany, Sept. 1, 2023 /PRNewswire/ -- EW Nutrition, a leading global provider of functional animal nutrition solutions, welcomes Jan Vanbrabant as its new Chief Executive Officer.
  • "We are very pleased that we have found a strong management lead in Jan, who embodies the philosophy of EW Nutrition", says Jan Wesjohann, Managing Director of parent company EW Group.
  • "I am very excited to be joining the EW Nutrition team," said Jan Vanbrabant.
  • EW Nutrition is uniquely positioned to support its customers in mastering the challenges of the changing animal health and nutrition environment."

EW Nutrition welcomes Jan Vanbrabant as new CEO

Retrieved on: 
Friday, September 1, 2023

VISBEK, Germany, Sept. 1, 2023 /PRNewswire/ -- EW Nutrition, a leading global provider of functional animal nutrition solutions, welcomes Jan Vanbrabant as its new Chief Executive Officer.

Key Points: 
  • VISBEK, Germany, Sept. 1, 2023 /PRNewswire/ -- EW Nutrition, a leading global provider of functional animal nutrition solutions, welcomes Jan Vanbrabant as its new Chief Executive Officer.
  • "We are very pleased that we have found a strong management lead in Jan, who embodies the philosophy of EW Nutrition", says Jan Wesjohann, Managing Director of parent company EW Group.
  • "I am very excited to be joining the EW Nutrition team," said Jan Vanbrabant.
  • EW Nutrition is uniquely positioned to support its customers in mastering the challenges of the changing animal health and nutrition environment."